NCT02013154 - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

May 5, 2014

Primary Completion Date

July 19, 2019

Study Completion Date

January 11, 2021

Conditions

Esophageal NeoplasmsAdenocarcinoma of the Gastroesophageal JunctionGastroesophageal CancerSquamous Cell CarcinomaGastric Adenocarcinoma

Interventions

DRUG

DKN-01 150 mg

Administered by IV infusion

DRUG

Paclitaxel

Administered by IV infusion

DRUG

Pembrolizumab

Administered by IV infusion

DRUG

DKN-01 300 mg

Administered by IV infusion

Trial Locations (10)

Duke University, Durham

Tennessee Oncology / Sarah Cannon Research Institute, Nashville

Vanderbilt University / VICC, Nashville

Northwestern University, Chicago

Mary Crowley Cancer Center, Dallas

CTRC @ The University of Texas Health Science Center at San Antonio, San Antonio

Cedars Sinai Medical Care Foundation, Los Angeles

Smilow Cancer Hospital at Yale - New Haven, New Haven

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston